



1642\$

Patent
Attorney Docket: 252/029

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

James M. Lipton
Anna P. Catania

Serial No.: 09/533,341

Filed: March 23, 2000

For: ANTIMICROBAL AND ANTI-
INFLAMMATORY PEPTIDES FOR
USE IN HUMAN
IMMUNODEFICIENCY VIRUS

Group Art Unit: 1642

Examiner: Parkin, J.

RECEIVED
DEC 28 2001
TECH CENTER 1600/2900

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

I. DOCUMENTS ENCLOSED:

Applicant submits the following documents with this Transmittal Letter.

- (1) Supplemental Information Disclosure Statement;
- (2) Form PTO-1449; and
- (3) References BU and DS.

LA-217629.5

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

December 13, 2001
Date of Deposit

Rachel Marquez

Name of Person Mailing Paper

Signature of Person Mailing Paper

12/17/2001 00006411 09533341 180 00-00
01 FC:120

II. REQUEST FOR EXTENSION OF TIME:

The proceedings herein are for a patent application and the provisions of 37 CFR § 1.136 apply.

- ☐ Applicant(s) petitions for an extension of time under 37 CFR § 1.136 [fees: 37 CFR § 1.17(a)(1)-(5)] for the total number of months checked below:

EXTENSION (months)	FEE FOR SMALL ENTITY	FEE FOR OTHER THAN SMALL ENTITY
<input type="checkbox"/> one month	\$55.00	\$110.00
<input type="checkbox"/> two months	\$195.00	\$390.00
<input type="checkbox"/> three months	\$445.00	\$890.00
<input type="checkbox"/> four months	\$695.00	\$1,390.00
<input type="checkbox"/> five months	\$945.00	\$1,890.00

Fee

- ☒ If any extension fee is required, please consider this a petition therefor.

III. FILING FEES

- ☐ Applicant claims small entity status pursuant to 37 CFR 1.27.

BASIC FILING FEE:							\$0.00
Total Claims	0	-	20	=	0	x \$18.00	\$0.00
Independent Claims		-	3	=	0	x \$80.00	\$0.00
Multiple Dependent Claims	\$270	(if applicable)				<input type="checkbox"/>	\$0.00
Surcharge 37 CFR § 1.16(e)	\$130	(if applicable)				<input type="checkbox"/>	\$0.00
TOTAL OF ABOVE CALCULATIONS							\$0.00
Reduction by ½ for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28.							<input type="checkbox"/> \$0.00
Extension of Time (from above)							\$0.00
Assignment -- \$40 (if applicable)							<input type="checkbox"/> \$0.00
TOTAL FEES SUBMITTED HEREWITH							\$0.00

IV. METHOD OF PAYMENT OF FEES:

- ☒ A check in the amount of \$180.00 is enclosed to cover fee for filing of Supplemental Disclosure Statement.
- ☐ Charge Lyon & Lyon's Deposit Account No. **12-2475** in the amount of \$____.

☒ The Commissioner is authorized to charge Lyon & Lyon's Deposit Account No. 12-2475 for any fees required under 37 CFR §§ 1.16, 1.17 and 1.445 that are not covered, in whole or in part, by a check enclosed herewith and to credit any overpayments to said Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

Dated: 12/13/01

By: 


Sandra Fujiyama
Reg. No. 46,713



22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP
Suite 4700
633 W. Fifth Street
Los Angeles, CA 90071
(213) 489-1600



RECEIVED
DEC 28 2001
TECH CENTER 1600/2900

Group Art Unit: 1642

Examiner: Parkin, J.

Filed: March 23, 2000

**For: ANTIMICROBIAL AND ANTI-
INFLAMMATORY PEPTIDES FOR USE IN
HUMAN IMMUNODEFICIENCY VIRUS**

Commissioner for Patents
Washington, D.C. 20231

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Supplemental Information Disclosure Statement (“IDS”) are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be “material” pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as “prior art” under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

The fee due under 37 CFR § 1.17(p) is submitted herewith.

12/27/2008 SFELEKE1 02000111 09533341

01 FC:126

100.00 09

PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:


A check in the amount of \$180.00 is enclosed for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,
LYON & LYON LLP

Dated: 12/13/01

By:


Sandra Fujiyama
Reg. No. 46,713



22249

LYON & LYON LLP
633 W. Fifth Street,
Suite 4700
Los Angeles, CA
90071